Advertisement

Drugs & Aging

, Volume 16, Issue 6, pp 391–395 | Cite as

Potential Role of Cannabinoids in Parkinson’s Disease

  • Jan ŠevčíkEmail author
  • Karel Mašek
Leading Article

Abstract

Parkinson’s disease (PD) is a neurodegenerative disorder caused by a progressive loss of dopaminergic neurons of the substantia nigra, resulting from an oxidative stress. The lack of dopaminergic neurons is reflected by a disturbed balance of the neural circuitry in the basal ganglia. Cannabinoids might alleviate some parkinsonian symptoms by their remarkable receptor-mediated modulatory action in the basal ganglia output nuclei. Moreover, it was recently observed that some cannabinoids are potent antioxidants that can protect neurons from death even without cannabinoid receptor activation. It seems that cannabinoids could delay or even stop progressive degeneration of brain dopaminergic systems, a process for which there is presently no prevention. In combination with currently used drugs, cannabinoids might represent, qualitatively, a new approach to the treatment of PD, making it more effective.

Keywords

Substantia Nigra Selegiline Cannabidiol Substantia Nigra Neuron Dexanabinol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Standaert DG, Young AB. Treatment of central nervous system degenerative disorders. In: Hardmann JG, Goodman Gilman A, Limbird LE, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 503–19Google Scholar
  2. 2.
    Gerlach M, Riederer P, Youdim MBH. Neuroprotective therapeutic strategies: comparison of experimental and clinical results. Biochem Pharmacol 1995 Jun; 50(1): 1–16PubMedCrossRefGoogle Scholar
  3. 3.
    Youdim MBH, Riederer P. Understanding Parkinson’s disease. Sci Am 1997 Jan; 276(1): 38–45CrossRefGoogle Scholar
  4. 4.
    Schapira AH, Mann VM, Cooper JM, et al. Anatomic and disease specificity of NADH CoQ 1 reductase (complex I) deficiency in Parkinson’s disease. J Neurochem 1990 Dec; 55(6): 2142–5PubMedCrossRefGoogle Scholar
  5. 5.
    Beal MR Excitotoxicity and nitric oxide in Parkinson’s disease pathogenesis. Ann Neurol 1998 Sep; 44 (3 Suppl. 1): S110–4Google Scholar
  6. 6.
    Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994 Mar 3; 330(9): 613–22PubMedCrossRefGoogle Scholar
  7. 7.
    Akaike A. Glutamate neurotoxicity and neuroprotective factors. Nippon Yakurigaku Zasshi 1994 May; 103(5): 193–201PubMedCrossRefGoogle Scholar
  8. 8.
    Cohen G, Werner P. Free radicals, oxidative stress and neurodegeneration. In: Calne DB, editor. Neurodegenerative diseases. Philadelphia (PA): W.B. Saunders, 1994: 139–61Google Scholar
  9. 9.
    Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson’s disease: evidence supporting it. Ann Neurol 1992 Dec; 32(6): 804–12PubMedCrossRefGoogle Scholar
  10. 10.
    Olanow CW. Oxidation reactions in Parkinson’s disease. Neurology 1990 Oct; 40 (10 Suppl. 3): 32–7PubMedGoogle Scholar
  11. 11.
    Jenner P. Oxidative stress as acause of Parkinson’s disease. Acta Neurol Scand Suppl. 1991; 136: 6–15PubMedCrossRefGoogle Scholar
  12. 12.
    Parkinson’s Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1993 Jan 21; 328(3): 176–83CrossRefGoogle Scholar
  13. 13.
    Mechoulam R. The pharmacohistory of Cannabis sativa. In: Mechoulam R, editor. Cannabinoids as therapeutic agents. Boca Raton (FL): CRC, 1986: 1–19Google Scholar
  14. 14.
    Gowers, WR. A manual of diseases of the nervous system. Vol. II. London: Churchill, 1888Google Scholar
  15. 15.
    Annas GJ. Reefer madness: the federal response to California’s medical-marijuana law. N Engl J Med 1997 Aug 7; 337(6): 435–9PubMedCrossRefGoogle Scholar
  16. 16.
    Mechoulam R, Vogel Z, Barg J. CNS cannabinoid receptors: role and therapeutic implications for CNS disorders. CNS Drugs 1994; 2(4): 255–60CrossRefGoogle Scholar
  17. 17.
    Devane WA. New dawn of cannabinoid pharmacology. Trends Pharmacol Sci 1994 Feb; 15(2): 40–1PubMedCrossRefGoogle Scholar
  18. 18.
    Devane WA, Dysarz III FA, Johnson MR, et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988 Nov; 34(5): 605–13PubMedGoogle Scholar
  19. 19.
    Klein TW, Newton C, Friedman H. Cannabinoid receptors and immunity. Immunol Today 1998 Aug; 19(8): 373–81PubMedCrossRefGoogle Scholar
  20. 20.
    Jeon YJ, Yang KH, Pulaski JT, et al. Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydro-cannabinol is mediated through the inhibition of nuclear factor- kappa B/Rel activation. Mol Pharmacol 1996 Aug; 50(2): 334–41PubMedGoogle Scholar
  21. 21.
    Bloom FE. Neurotransmission and the central nervous system. In: Hardmann JG, Goodman Gilman A, Limbird LE, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 267–93Google Scholar
  22. 22.
    Skaper SD, Buriani A, Dal Toso R, et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci U S A 1996 Apr 30; 93(9): 3984–9PubMedCrossRefGoogle Scholar
  23. 23.
    Hampson AJ, Bornheim LM, Scanziani M, et al. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J Neurochem 1998 Feb; 70(2): 671–6PubMedCrossRefGoogle Scholar
  24. 24.
    Shen M, Thayer SA. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol Pharmacol 1998 Sep; 54(3): 459–62PubMedGoogle Scholar
  25. 25.
    Biegon A. Neuroprotective activity of HU-211, a novel nonpsychotropic synthetic cannabinoid. Ann N Y Acad Sci 1995 Sep 15; 765: 314PubMedCrossRefGoogle Scholar
  26. 26.
    Eshhar N, Striem S, Kohen R, et al. Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist. Eur J Pharmacol 1995 Sep 5; 283(1–3): 19–29PubMedCrossRefGoogle Scholar
  27. 27.
    Hampson AJ, Grimaldi M, Axelrod J, et al. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 1998 Jul 7; 95(14): 8268–73PubMedCrossRefGoogle Scholar
  28. 28.
    Mansbach RS, Rovetti CC, Winston EN, et al. Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats. Psychopharmacology (Berl) 1996 Apr; 124(4): 315–22CrossRefGoogle Scholar
  29. 29.
    Cunha JM, Carlini EA, Pereira AE, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980; 21(3): 175–85PubMedCrossRefGoogle Scholar
  30. 30.
    Consroe P, Laguna J, Allender J, et al. Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol Biochem Behav 1991 Nov; 40(3): 701–8PubMedCrossRefGoogle Scholar
  31. 31.
    Sanudo-Pena MC, Patrick SL, Patrick RL, et al. Effects of intranigral cannabinoids on rotational behavior in rats: interactions with the dopaminergic system. Neurosci Lett 1996 Mar 8; 206(1): 21–4PubMedCrossRefGoogle Scholar
  32. 32.
    Sanudo-Pena MC, Walker JM. Role of the subthalamic nucleus on cannabinoid actions in the substantia nigra of the rat. J Neurophysiol 1997 Mar; 77(3): 1635–8PubMedGoogle Scholar
  33. 33.
    Sanudo-Pena MC, Walker JM. Effects of intrapallidal cannabinoids on rotational behavior in rats: interactions with the dopaminergic system. Synapse 1998 Jan; 28(1): 27–32PubMedCrossRefGoogle Scholar
  34. 34.
    Sanudo-Pena MC, Tsou K, Walker JM. Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci 1999; 65(6/7): 703–13PubMedCrossRefGoogle Scholar
  35. 35.
    Sanudo-Pena MC, Patrick SL, Khen S, et al. Cannabinoid effects in basal ganglia in a rat model of Parkinson’s disease. Neurosci Lett 1998 Jun 5; 248(3): 171–4PubMedCrossRefGoogle Scholar
  36. 36.
    Muller-Vahl KR, Kolbe H, Schneider U, et al. Cannabis in movement disorders. Forschende Komplementarmedi 1999 Oct; 6Suppl. 3: 23–7CrossRefGoogle Scholar
  37. 37.
    Brotchie JM. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson’s disease. Mov Disord 1998 Nov; 13(6): 871–6PubMedCrossRefGoogle Scholar
  38. 38.
    Frankel JP, Hughes A, Lees AJ, et al. Marijuana for Parkinsonian tremor. J Neurol Neurosurg Psychiatry 1990 May; 53(5): 436–42PubMedCrossRefGoogle Scholar
  39. 39.
    Agid Y, Chase T, Marsden D. Adverse reactions to levodopa: drug toxicity or progression of disease? Lancet 1998 Mar 21; 351(9106): 851–2PubMedCrossRefGoogle Scholar
  40. 40.
    Stix G. Herb remedy. Sci Am 1998 Sep; 279(3): 11–12Google Scholar
  41. 41.
    Grotenhermen F. Therapeutic use of cannabis. Lancet 1998 Mar 7; 351(9104): 758–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  1. 1.Institute of PharmacologyAcademy of Sciences of the Czech RepublicPrague 4Czech Republic

Personalised recommendations